Ionis receives $40M Spinraza milestone from Biogen

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) received a $40 million milestone payment from Biogen Inc. (NASDAQ:BIIB) triggered by pricing approval of Spinraza nusinersen in Japan. The antisense oligonucleotide that modulates splicing of survival of motor neuron 2 centromeric (SMN2) mRNA was approved in Japan in June to treat infantile-onset spinal muscular atrophy (SMA)...